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Abstract  
 
Due to the incidence of diabetes and the related morbidity of diabetic nephropathy, identification of 
new therapeutic strategies represents a priority. In the last few decades new and growing evidence 
on the possible role of histamine in diabetes has been provided. In particular, the histamine receptor 
H4R is emerging as a new promising pharmacological target for diabetic nephropathy. The aim of 
this study was to evaluate the efficacy of selective H4R antagonism by JNJ39758979 on the 
prevention of diabetic nephropathy progression in a murine model of diabetes induced by 
streptozotocin injection.  JNJ39758979 (25, 50, 100 mg/kg/day p.o.) was administered for 15 weeks 
starting from the onset of diabetes. Functional parameters were monitored throughout the 
experimental period.  
JNJ39758979 did not significantly affect glycaemic status or body weight. The urine analysis 
indicated a dose-dependent inhibitory effect of JNJ39758979 on Albumin-Creatinine-Ratio, the 
Creatinine Clearance, the 24 h urine volume, and pH urine acidification (P < 0.05). The beneficial 
effects of JNJ39758979 on renal function paralleled comparable effects on renal morphological 
integrity. These effects were sustained by a significant immune infiltration and fibrosis reduction. 
Notably, megalin and sodium-hydrogen-exchanger 3 expression levels were preserved.  
Our data suggest that the H4R participates in diabetic nephropathy progression through both a direct 
effect on tubular reabsorption and an indirect action on renal tissue architecture via inflammatory 
cell recruitment. Therefore, H4R antagonism emerges as a possible new multi-mechanism 
therapeutic approach to counteract development of diabetic nephropathy development. 
 
Keywords: kidney; diabetes; histamine, histamine H4R antagonist, JNJ39758979, diabetic 
nephropathy 
 
 
 
Non-standard Abbreviations 
ACR = Albumin-Creatinine-Ratio; AQP= Aquaporin; CrCl = Creatinine Clearance; ESRD = End 
Stage Renal Disease; GBM = Glomerular Basement Membrane; HDC = Histidine Decarboxylase; 
H&E = Haematoxylin and Eosin; HPLC = High Performance Liquid Chromatography; H1-4Rs = 
Histamine H1-4 Receptors; IL = Interleukin; IP = Interferon gamma-induced Protein; LRP-2 = low 
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density lipoprotein-related protein-2 (megalin) gene; MCP = monocyte chemoattractant protein; 
NHE3 = Sodium-Hydrogen Exchanger 3; OKP cells = Opossum Kidney Cells; PAS = Periodic 
Acid Schiff; PMNs = Polymorphonuclear Neutrophils; RAS = renin-angiotensin-system; RT = 
reverse-transcription; SD = Slit Diaphragm; STZ = streptozotocin; TGF-ß = Transforming Growth 
Factor-ß; THP = Tamm–Horsfall glycoprotein; UPE = Urinary Protein Excretion 
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1 Introduction 
The incidence of diabetes is expected to exceed 592 million by 2030 [1], is alarmingly increasing 
the rate of microvascular complications including diabetic nephropathy.  
With about one-third of diabetic patients developing diabetic nephropathy, this complication is one 
of the most important challenges to clinical and public health [2]. Despite the benefits afforded by a 
therapy mainly based on the modulation of the renin-angiotensin system (RAS) [3], incidence of the 
overall progression of diabetic nephropathy remains unacceptably high [4]. Haemodialysis and 
transplantation are the only therapeutic options available when End Stage Renal Disease (ESRD) 
occurs. Therefore, to improve health outcomes and reduce the societal burden, the pursuit of 
innovative effective therapeutic strategies for the treatment of diabetic nephropathy is clearly 
warranted. 
Interestingly, histamine is emerging as a new mediator in diabetic nephropathy [5]. Histamine is a 
pleiotropic amine, historically implicated in several immune-inflammatory processes. It acts 
through four subtypes of G-protein coupled receptors, named histamine H1-4 receptors (H1-4Rs), which 
are differentially expressed in various organs, including the kidney included [6-9]. Histamine 
synthesis is catalysed by the rate-limiting enzyme histidine decarboxylase (HDC), mainly expressed 
in the “professional” mast cell. However, HDC has been also found in the proximal tubule and 
human podocytes [9-11]. Actually, the first evidence for a possible role of histamine in diabetic 
nephropathy was provided in the 1960s when, concurrent with an increased tissue HDC activity, an 
increased level of this amine was observed in the kidney of diabetic animals [12, 13]. In particular, 
histamine has already been demonstrated to increase salt and water excretion [14-16] and renin 
release [17], and to decrease the ultrafiltration coefficient [18]. These effects were classically 
attributed to the well-known vasoactive properties of the amine. However, different lines of 
evidence point out to a potential direct contribution of histamine to the renal pathophysiology, far 
beyond its effect on glomerular microcirculation hemodynamic [5]. Histamine was found to 
increase fasting-induced apoptosis in tubules [19]. Moreover, the increased number of the 
tubulointerstitial mast cells and their degranulation consequent to diabetic nephropathy progression 
are suggestive of a direct contribution by histamine to renal inflammation and fibrosis [19, 20]. The 
use of a mast cells stabiliser afforded protection against renal dysfunction in a high fat diet rat 
model [21].  
Recently, compelling evidence pointing to the H4R as a possible target for diabetic nephropathy was 
provided. We reported both the H4R expression on epithelial tubular cells [8] and its significant 
over-expression in the kidney of diabetic rats [6]. Moreover, our pilot data are indicative of a 
positive correlation between renal H4R expression and albuminuria in a model of murine diabetes 
[22]. Therefore, the intriguing potential of H4R antagonism as a new pharmacological and 
therapeutic approach for diabetic nephropathy has become evident. 
In comparison to other the different selective H4R antagonists, JNJ39758979 [(R)-4-(3-amino-
pyrrolidin-1-yl)-6-isopropyl-pyrimidin-2-ylamine][23] offers the following advantages: (i) is orally 
bioavailable; (ii) has a long half life (126-157 h for a single dose); (iii) rapidly reaches the kidney 
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(mean tmax 2.0 h), from which it is slowly eliminated (22.3 h; kidney to plasma ratio 95.8); (iv) is 
metabolically stable (t1/2 in vitro 120 min); (v) does not inhibit the cytochrome P450 (CYP) 
isoforms; (vi) have a low fluctuation index (from 0.852 to 2.60) thus allowing a once daily chronic 
administration [24]. Therefore, the primary aim of this study was to evaluate whether JNJ39758979 
is able to preserve renal morphological and functional integrity in a murine model of diabetic 
nephropathy. 
 
2 Methods 
2.1 Materials 
All chemicals, not otherwise indicated and rabbit polyclonal anti‐β‐actin antibody (A2066), were 
from Sigma Aldrich (St. Louis, MO, USA). JNJ39758979 was synthesised by Janssen Research & 
Development, LLC as previously described [23].  
The Glucocard MX Blood Glucose Meter was from A. Menarini Diagnostic (Florence, IT). The 
Albumin enzymatic immunoassay kits ELISA Quantitation Set was from Bethyl Laboratories, Inc. 
(Montgomery, TX, USA).  
The goat polyclonal anti-Megalin (sc-515750, lot number L2104), the goat polyclonal anti-H4R (sc-
33967, lot number L0913) the rabbit polyclonal anti-aquaporin (AQP)1 (sc-20810, lot number 
B0210), the rabbit polyclonal anti-Tamm–Horsfall glycoprotein (THP; sc-20631, lot number 
A0611) and the rabbit polyclonal anti-AQP2 (sc-28629, lot number G1713) antibodies were from 
Santa Cruz Biotechnology (Dallas, Texas, USA), the rabbit polyclonal anti‐NHE3 (GTX41967, lot 
number 821700650) was from Gentex (San Antonio, TX, USA). The rabbit peroxidase‐labelled 
secondary antibody was from Cell Signaling Thecnology, Inc. (Danvers, MA, USA). The donkey 
anti-goat Fluor 568- conjugated IgG was purchased from Thermofisher Scientific (Waltham, MA, 
USA), while the Alexa Fluor 594 AffiniPure bovine anti-goat and the Alexa Fluor 488 AffiniPure 
donkey anti-rabbit were from Jackson ImmunoResearch Laboratories, Inc. (West Grove, PA, USA).  
TRIzol Reagent, the Taqman gene expression assay reagents and probes, the Optical 96-well plates 
and the micro‐BCA™ Protein Assay Kit were from Thermofisher Scientific. The cDNA Synthesis 
Kit and the ECL substrate were from BioRad (Foster City, CA, USA). The nitrocellulose 
membranes were from GE Healthcare life Sciences (Milano, IT). 
 
2.2 Animal Care and ethics statement 
Five-six week old (20.74 ± 2.58 g body weight) male DBA2/J mice (Charles River Laboratories, 
Calco, IT) were maintained in compliance with the European Directive 2010/63/EU on the 
protection of animals used for scientific purposes, housed in a controlled environment at 25 ± 2°C 
with alternating 12-hour light and dark cycles and fed with a standard diet during a 1-week 
adaptation period, fed with a standard pellet diet (Piccioni, Settimo Milanese, Milan, IT) and 
watered ad libitum. The scientific project was approved by the “Animal Use and Care Committee’’ 
of the Turin University. In order to reduce the number of animals, the minimum sample size of 10 
animals/group, randomly assessed according to a simple randomisation design, was determined by 
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applying the Fleiss test for an unmatched case-control study as power analysis [25]. Confidence 
interval was 90%, and the power was at 85% and the alpha level was set at 0.05. This design 
provides the power to investigate the differences in renal function between, not only normal and 
diabetic control mice, but also between diabetic and treated mice.  
 
2.3 Induction of diabetes 
Hyperglycaemia was induced in DBA2/J 7-8 week old mice (this inbred mouse strain being the 
most susceptible to diabetic nephropathy) by multiple low-dose streptozotocin (STZ)-injection (50 
mg/kg day STZ freshly made in 0.1 mol/l citrate buffer, pH 4.5) i.p. for 5 consecutive days, thus to 
avoid acute STZ toxicity, according to the Animals Models of Diabetic Complications Consortium 
guidelines (available at http://www.amdcc.org). Control animals were treated with vehicle alone. 
The onset of diabetes was evaluated by measuring 6 h fasting blood glucose. Blood glucose was 
then measured fortnightly using a Glucocard MX Blood Glucose Meter. Weight, food and water 
intake were recorded on a weekly basis. Diabetes was defined as fasting blood glucose level ≥ 200 
mg/dl. After the onset of diabetes, the selective H4R antagonist JNJ39758979 was administered 
daily for 15 weeks as a water solution by oral gavage at 25, 50, 100 mg/kg. Fifteen weeks after 
diabetes onset, mice were anaesthetised with isofluorane and killed by cardiac exsanguination; 
blood and kidneys were collected for biochemical and morphological analyses. Data recording and 
data analysis were blinded to both the operators and the analysts, with only the individual 
administered the drug aware of the drug treatments given. Moreover, animal specimens were 
randomly labelled by a unique numeric code by AP and ACR, to guarantee blind tissue sample 
processes.  
 
2.4 Renal function evaluations  
Twenty-four-hours urine collection was performed using metabolic cages. Urine volume and pH 
were determined. All analyses were run in triplicate. Proteinuria was measured by the Bradford 
method using Bovine Serum Albumin as standard [26]. Albuminuria was determined by ELISA, 
according to the manufacturer’s instruction; the analysis was performed in duplicate. 
Creatinine was determined by a High Performance Liquid Chromatography (HPLC) reverse phase 
method [27, 28]. A more comprehensive description is found in Supplementary materials.  
 
2.5 Morphological analysis 
Renal samples collected at sacrifice were fixed by immersion in 4% paraformaldehyde, dehydrated 
in graded ethanol, paraffin embedded and cut in 5 μm thick sections. Histological slides were 
stained with haematoxylin and eosin (H&E) to evaluate alterations of gross tissue architecture; with 
periodic acid Schiff (PAS) to quantify glomerular damage; and 0.1% picrosirius red for the renal 
collagen content assessment. Stained sections were examined and pictures were taken with a Zeiss 
Axioskop microscope (Zeiss, Mannheim, DE) at 25X, 100X or 10X magnification, respectively. 
Morphological measurement details have been provided in Supplementary Materials.  
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2.6 Immunofluorescence analysis 
Megalin immunoreactivity was determined on 5 μm thick tissue sections. The sections were 
deparaffinised and re-hydrated, followed by microwave antigen retrieval in 10 mM sodium citrate, 
pH 6.0. After incubation in 1.5% bovine serum albumin in PBS, pH 7.4 for 20 min at RT to 
minimise non-specific binding, renal sections were incubated overnight with goat polyclonal anti-
Megalin (1:50). The immunoreactions were revealed by incubation with donkey anti-goat Fluor 
568-conjugated IgG (1:350) for 2 h at RT. Negative controls were carried out by omitting the 
primary antiserum. The immunoreaction products were observed under an epifluorescence Zeiss 
Axioskop microscope at 40X magnification and quantified as described in Supplementary 
Materials. For the co-localization analysis, after antigen retrieval (sodium citrate 10 mM pH 6.9 
for 3 cycles of 20 s in microwave 750 W) and blocking, the sections were incubated overnight 
with goat polyclonal anti-H4 receptor and rabbit polyclonal anti-THP, anti-AQP1 or anti-AQP2 
(1:50) antibodies, followed by incubation with the Alexa Fluor 594 AffiniPure bovine anti-goat or 
the Alexa Fluor 488 AffiniPure donkey anti-rabbit. After counterstaining with DAPI, 
photomicrographs were obtained by Apotome systems (Zeiss) using a x40 objective. 
 
2.7 Transmission Electron Microscopy 
The preparation of the renal biopsies for electron microscopy was performed according to 
standardised procedures. The sample were cut into 1 mm3 pieces, fixed in 4% glutaraldehyde 
(phosphate buffered, pH 7.2) and 1% osmium tetroxide and embedded in Epon 812 (Fluka-Sigma-
Aldrich, Milan, IT). After ultra-thin sectioning, the samples were post-stained with uranyl acetate 
and alkaline bismuth subnitrate and examined under a JEM 1010 electron microscope (Jeol, Tokyo, 
JP) at 80 kV. At least two glomeruli were analysed from each sample. To quantify the 
ultrastructural alterations of the filtration barrier, the number of slit diaphragms and foot processes 
per 10 μm and the foot processes base width, were measured. The counting was performed on a 
randomly determined area of the glomerular capillary wall. To test the reliability of the 
morphological analysis, the measurements were carried out twice. 
 
2.8 qPCR 
One hundred micrograms of total RNA, extracted according to Supplementary Materials, was 
reverse transcribed to single-stranded cDNA using the commercially available i-script cDNA 
Synthesis Kit, according to the manufacturer’s instructions. Negative controls of the reverse-
transcription (RT) were carried out omitting the enzyme or substituting RNA with RNAse-free 
water, to exclude DNA or RNA contamination, respectively. qPCR for the quantification of the 
transcript level of low density lipoprotein-related protein (LRP)-2 was performed using the ABI 
Prism 7500 Sequence Detection System instrument (Thermofisher Scientific) and hydrolysis probes 
(Mm01328171_m1). PCR amplifications, run in triplicate, were performed in Optical 96-well plates 
on cDNA samples corresponding to a final RNA concentration of 50 ng. In each run blank controls, 
no template (water) or RT-negative reactions, were performed. Quantification cycle Cq values were 
analysed. All values were normalised to the 18S ribosomal reference gene (Mm02601777_g1) 
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using the 2−ΔΔCq method and fold-change expression with respect to control was calculated for all 
samples. 
 
2.9 Immunoblotting 
Kidney specimens randomly selected from 5 animals/group were lysed in cold buffer (10 mM 
Tris/HCl pH 7.4, 10 mM NaCl, 1.5 mM, MgCl2, 2 mM Na2 EDTA, 1% Triton X‐100), 
supplemented with 10× Sigmafast Protease Inhibitor cocktail tablets. Total protein content was 
measured spectrophotometrically using a micro‐BCA™ Protein Assay Kit. Sixty microgram of total 
proteins were randomly electrophoresed by SDS‐PAGE and blotted onto nitrocellulose membranes. 
The membranes were incubated overnight at 4°C with rabbit polyclonal anti-sodium-hydrogen 
exchanger (NHE)3 (1:1000) and rabbit polyclonal anti‐β‐actin antibodies (1:20000), assuming β‐
actin as control invariant protein. Specific bands were detected using rabbit peroxidase‐labelled 
secondary antibody (1:2000) and enhanced chemiluminescent (ECL) substrate. Densitometric 
analysis was performed by ImageJ 1.41 (NIH, USA) software. Fold-change expression with respect 
to control was calculated for all samples. 
 
2.10 Statistical analysis 
For each assay, data were reported as mean values (± standard error of the mean, S.E.M.) of 
individual average measures of the different animals per group. The test for normality using the 
Kolmogorov-Smirnov followed by the one-way ANOVA and the post hoc Tukey test for multiple 
comparisons were performed when there was a variance homogeneity, otherwise for the LRP-2 and 
HNE3 relative expression the non-parametric Kruskal-Wallis test was used. Calculations were 
made with Prism 5 statistical software (GraphPad Software, Inc., San Diego, CA, USA). A 
probability value (P) of < 0.05 was considered significant. 
 
3 Results 
3.1 Effect of JNJ39758979 on blood glucose level and body weight 
One week after the last STZ injection, more than half of DBA2/J mice developed a hyperglycaemic 
status (≥ 200 mg/dl), compatible with the definition of diabetes in mice [29]. The glycaemic level 
increased to over 200 mg/dl in all the diabetic animals (n = 40) within 21 days, remaining severe (P 
< 0.05 vs control) throughout the experimental period. No statistical difference in hyperglycaemia 
was observed between the diabetic groups, with JNJ39758979 not affecting the glycaemic status, 
irrespective of the dose treatment (Fig. 1a). 
Consistently with the glycaemic status, only the control animals displayed an increase in body 
weight, whereas the STZ mice body weights were significant reduced irrespectively of the drug 
treatment (n = 10/group, P < 0.05 vs control; Fig. 1b). No insulin treatment was administered during 
the study in any mouse. 
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Fig. 1. Effect evoked by JNJ39758979 on metabolic parameters at 15 weeks after 
diabetes onset.  Six hour fasting glucose level (a) and body weight (b) measurements. Data are 
expressed as the mean ± S.E.M. (n = 10/group); *P < 0.05 vs CTRL. 
 
3.2 JNJ39758979 preserves renal function  
The urine analysis at 15 weeks of diabetes showed a dose-response beneficial effect of 
JNJ39758979. The urine volume, robustly increased in STZ mice, was dose-dependently reduced in 
JNJ39758979-treated mice. JNJ39758979 at 100 mg/kg also restored the water to urine ratio to 
control levels (Table 1). Moreover, mice treated with JNJ39758979 at 100 mg/kg showed a 
significant increase in urine pH compared to STZ mice (Table 1). Most notably, diabetic animals 
showed a significant increase in Urinary Protein Excretion (UPE), Albumin-Creatinine-Ratio 
(ACR) and a parallel significant drop in the Creatinine Clearance (CrCl), suggestive of a renal 
failure coherent with the duration of severe hyperglycaemia. JNJ39758979 at the highest dose was 
effective in ameliorating UPE and restoring the ACR and the CrCl to the control level (Table 1) 
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Table 1. Renal Function param
eters at week 15 after diabetes onset 
Treatm
ent 
Urine 
volum
e/24 h 
(m
L) 
Urine pH 
W
ater to Urine 
ratio (%
) 
UPE 
(m
g/24 h) 
 
ACR  
(µg/m
g) 
CrCl 
(m
l/m
in) 
CTRL 
0.51 ± 0.22 
6.27 ± 0.12 
 25 ± 4.03 
3.29 ± 0.38 
27.73 ± 9.00 
0.11 ± 0.01 
STZ 
28.00 ± 3.15* 
5.16 ± 0.10* 
78.4 ± 9.78* 
96.78 ± 8.79* 
524.68 ± 60.52* 
0.02 ± 0.00* 
STZ + JNJ 25 m
g/kg 
20.57 ± 8.71* 
5.10 ± 0.10* 
55.74 ± 12.19* 
74.69 ± 3.67* 
439.06 ± 116.14* 
0.04 ± 0.01* 
STZ + JNJ 50 m
g/kg 
18.00 ± 4.24
# 
5.20 ± 0.11* 
52.50 ± 8.78* 
55.93 ± 2.53*
# 
255.58 ± 33.93*
# 
0.06 ± 0.02* 
STZ + JNJ 100 
m
g/kg 
10.00 ± 0.53
# 
5.76 ± 0.12*
# 
32.56 ± 5.12
# 
41.62 ± 5.69*
# 
36.04 ± 10.50
# 
0.12 ± 0.07
# 
*P < 0.05 vs CTRL 
#P < 0.05 vs STZ 
UPE = Urinary Protein Excretion 
ACR = Albumin Creatinine Ratio 
CrCl = Creatinine Clereance 
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3.3 JNJ39758979 prevents glomerular structure alterations 
The beneficial effects displayed by JNJ39758979 on renal function were accompanied and 
supported by the maintenance of tissue morphological structure. As reported in Fig. 2, the 
mesangial matrix expansion induced by STZ (n = 10/group, P < 0.05) was significantly reduced in a 
dose-dependent manner by JNJ39758979. Interestingly, the presence of nodule lesions found in the 
STZ-treated animals was consistent with the development of nodular sclerosis described in the III 
class classification of glomerular lesions in diabetic nephropathy [30]. The lesion was still 
identified in the animals treated with JNJ39758979 at 25 mg/kg, but not in the 50 mg/kg or in the 
100 mg/kg groups (Fig. 2). These results confirmed the efficacy of JNJ39758979 at inhibiting 
diabetic nephropathy development. 
 
Fig. 2. Effect evoked by JNJ39758979 on morphological lesions. PAS staining from 
renal sections. Arrows highlight mesangial matrix expansion while stars indicate nodular lesions. 
Micrographs at 100X magnification are representative of 10 animals/group. The densitometric 
analysis is expressed as the mean ± S.E.M. (n = 10); *P < 0.05 vs CTRL, #P < 0.05 vs STZ. 
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The electron microscopy analysis reported in Fig. 3 showed pathological glomerular alterations in 
STZ mice coherent with the disease model used. In particular, the quantitative analysis performed 
on the glomerular filtration barrier clearly confirmed a significant increase in podocyte foot process 
loss, as showed by the increased foot process base width (Fig. 3b; P < 0.05) with a parallel 
reduction in the number of foot processes (Fig. 3c; P < 0.05) and slit diaphragm (SD)/10 μm (Fig. 
3d; P < 0.05). JNJ39758979 prevented the glomerular structure alterations induced by STZ in a 
dose-dependent manner, with the highest doses effective on podocyte effacement (Fig. 3; P < 0.05). 
   
Fig. 3. Effect evoked by JNJ39758979 on glomerular morphology. EM micrographs 
showing ultrathin podocyte sections. Micrographs at 20K magnification are representative of 10 
animals/group (a). Foot processes base width (b), number of podocyte foot processes/10 µm of 
GMB (c) and (d) number of SD/10 µm were quantified. The densitometric analysis is expressed as 
the mean ± S.E.M. (n = 10); *P < 0.05 vs CTRL, #P < 0.05 vs STZ. 
3.4 JNJ39758979 prevents renal fibrosis decreasing inflammation process  
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The pathological alterations we observed have been correlated with an affected glomerular 
hemodynamic caused by a pro-inflammatory milieu. Based on the well-known role of histamine in 
inflammation and the contribution of H4R in polymorphonuclear neutrophils (PMNs) chemotaxis 
[31], we evaluated the effect of JNJ39758979 on the renal presence of infiltrating immune cells. 
H&E staining, shown in Fig. 4a, revealed a profound increase in renal cellularity, consisting with 
infiltration, in STZ mice. The administration of JNJ39758979 reduced the hyper-cellularity, 
irrespective of the dosage. Consistent with inflammatory cell infiltration, STZ mice showed a 
pronounced interstitial fibrosis demonstrated by collagen fibre deposition (Fig. 4b). The treatment 
with JNJ39758979 at 50 and 100 mg/kg significantly blunted the collagen deposition induced by 
STZ (n = 10/group, P < 0.05). 
 
Fig. 4. Effect evoked by JNJ39758979 on tubular interstitial infiltration and renal 
fibrosis. (a) Hematoxylin/Eosin staining from renal sections. Arrows highlight infiltrating cells. 
Micrographs at 25X magnification are representative of 10 animals/group. (b) Collagen deposition 
in the renal interstitium evaluated by picrosirius red stating. Micrographs at 10X magnification are 
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representative of 10 animals/group. The densitometric analysis is expressed as the mean ± S.E.M. 
(n = 10); *P < 0.05 vs CTRL, #P < 0.05 vs STZ. 
 
3.5 Effect of JNJ39758979 on tubular reabsorption processes  
The immunofluorescence analysis of histamine H4R demonstrated a clear tubular localization of this 
receptor, which was expressed on the proximal tubules as demonstrated by its co-presence with the 
proximal tubule marker, AQP1 (Fig 5). Interestingly, no co-localization was found with THP, 
marker of the thick ascending limb of the loop of Henlé, or AQP2, marker of the principal cells of 
the collecting duct (Fig 5).  
 
Fig. 5. H 4R tubular expression in DBA2/J mice. Immunofluorescence stain showing co-
localization of H4R (red) with AQP1-, THP- or AQP2-positive cells (green). Nuclei were stained 
with DAPI (blue). Micrographs at 40X magnification are representative of 10 animals. 
 
Therefore, a possible direct effect of JNJ39758979 on tubular reabsorptive process was 
investigated. As shown in Fig. 6, JNJ39758979 was able to prevent the reduction in megalin mRNA 
(Fig. 6a) and protein expression (Fig. 6b and 6c) induced by STZ, irrespective of the dosage (n = 
10/group, P < 0.05), thus suggesting a direct effect of the drug tested on tubular reabsorption. As 
megalin expression is inversely correlated with that of NHE3 [32], we also evaluated the effect of 
JNJ39758979 on the expression of this important exchanger. Consistently, the drug at 50 and 100 
mg/kg was effective in preventing the up-regulation of NHE3 expression induced by STZ (n = 
5/group, P < 0.05; Fig. 6d). 
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Fig. 6. Effect evoked by JNJ39758979 on megalin tubular expression. LRP-2 
expression by qPCR was determined on kidney specimens. Results are expressed as mean ± S.E.M. 
of in 10 animals/group; *P < 0.05 vs CTRL, #P < 0.05 vs STZ (a). Megalin expression on tubular 
epithelial cells was determined by immunofluorescence analysis. Micrographs at 40X magnification 
are representative of 10 animals/group (b). Densitometric analysis of Megalin expression 
determined by immunofluorescence analysis. Expression levels over control are expressed as the 
mean ± S.E.M. (n = 10); *P < 0.05 vs CTRL, #P < 0.05 vs STZ (c). NHE3 expression in kidney 
tissue was determined by immunoblotting; representative radiograph is shown. Expression levels, 
normalized to β-actin, are expressed as fold-increase over control, mean ± S.E.M. of 5 
animals/group; *P < 0.05 vs CTRL, #P < 0.05 vs STZ (d). 
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The data herein reported demonstrate a potential beneficial effect of H4R antagonism on the 
progression of diabetic nephropathy. This study was based on the assumption that the renal content 
of histamine, due to an increase in HDC activity, as well as H4R expression [6], are boosted in a 
diabetic condition [12, 13]. These two conditions also occurred in our present mouse model 
(Supplementary Fig. 1 and Fig. 2a). Interestingly, we confirmed the epithelial renal cells as a local 
source of histamine. Indeed, as reported in Supplementary Fig. 1 and consistent with previous data 
in the literature [9-11], HDC enzyme is expressed by residential cells both within the glomerulus 
and the tubules.  
In this present study the H4R antagonism was achieved by the JNJ39758979, a compound whose 
preclinical profile has already been characterised and the dose-response effects observed in this 
study were similar to that seen in other chronic models [33, 34]. The drug was administered using a 
preventive protocol, starting at the early onset of diabetes. Therefore, our study implicates a key 
role for H4R in diabetic nephropathy progression. Moreover, our data reveal a direct contribution of 
H4R antagonism in preserving renal integrity and function. Indeed, JNJ39758979 did not affect 
either the glycaemic status or the catabolic status of diabetic mice, but it was effective in 
counteracting the alterations of renal function parameters, such as ACR and CrCl. 
The dose-dependent reduction in both ACR and CrCl parameters provides strong evidence for a 
direct involvement of the H4R in regulating tubular reabsorption mechanism(s), consistent with the 
tubular distribution of the H4R, previously demonstrated by our group [6, 8] and, herein, further 
confirmed. Interestingly, in DBA2/J mice the H4R co-localized with AQP1, marker of the proximal 
tubule epithelial cells. A similar localization was reported for humans [8], but not for rats [6]. 
Therefore, the already observed widespread inter-species differences in H4R expression [6, 8] has 
been once confirmed once again.  
The hypothesis of a direct involvement of the H4R in regulating tubular reabsorption mechanism(s) 
is further strengthened by the ability of JNJ39758979 to preserve megalin expression down-
regulated by STZ. The maintenance of megalin expression on the apical domain of tubular 
epithelial cells has been suggested as an important defence mechanism. Indeed, megalin preserves 
and reclaims albumin throughout tubular reabsorption [35]. An increase in tubular reabsorption has 
been recognised as a defence mechanism following hyperfiltration [36]. Therefore, according to the 
“tubule-centric” hypothesis of diabetic nephropathy etiopathogenesis [37], megalin sustained 
expression could represent one of the mechanisms by which JNJ39758979 is able to maintain the 
structural integrity of the glomerulus. The effect on NHE3, a Na+/H+ exchanger on renal proximal 
tubules, could account for the prevention of both urinary acidosis and albuminuria observed for 
JNJ39758979 at 100 mg/kg. Interestingly, our data furnish the first evidence for a role of 
JNJ39758979 in regulating H+ efflux/transport across membranes. JNJ39758979 reduced NHE3 
expression in diabetic mice. Interestingly, this transporter is under the strict regulation of the renin-
angiotensin-system (RAS) and the inhibition of the RAS system has been previously demonstrated 
to affect NHE3 expression; in particular, losartan was reported to reduce NHE3 expression in 
opossum kidney (OKP) cells [38]. Looking at the pathways involved in both the AT1 and H4R 
signalling, interesting similarities could be noted, e.g. both being Gi-coupled protein receptors. 
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Therefore, analogous to the AT1/Gi pathway [38], we could speculate that the NHE3 expression at 
the proximal tubular level could be modulated by the H4R/Gi pathway [39, 40]. Moreover, 
independent, although contrasting, evidence is suggestive of interplay between RAS and histamine. 
For instance, histamine has been reported to stimulate renin release from the isolated perfused rat 
kidney [17], but H4R was reported to inhibit cardiac mast cell renin release in ischemia/reperfusion 
[41]. Therefore, it is possible that the effect of JNJ39758979 on NHE3 expression could be 
secondary to RAS modulation. 
Interestingly, these studies allow further speculations about the multifarious roles of histamine in 
acid/base homeostasis. Indeed, the properties of this amine in the gastric acid balance through H2R 
are well recognised since H2R antagonists entered the market as anti-acid drugs many years ago. 
More recently, it was also demonstrated that H3R activation in cardiac sympathetic nerves results in 
decreased NHE3 activity [42]. 
Collectively, the ability of JNJ39758979 to affect megalin and NHE3 expression is suggestive of a 
preserved ability to concentrate urine. The drug at 100 mg/kg was able to significantly decrease 
water to urine ratio, which was profoundly different in normal and diabetic animals, with the first 
excreting around 25% and the latter around 80% of their water intake. These data strongly supports 
the mechanistic hypothesis based on the beneficial effect of the compound tested on renal re-uptake. 
JNJ39758979 displayed a dose-dependent effect in reducing the urine volume, although the basal 
level was not restored. Notably, as no statistical differences were observed in the glycaemic level 
between the different diabetic groups, a direct effect on the proximal tubule, more than the diabetes 
status, could account for the urine volume reduction observed. Indeed, the tubule fluid that is 
delivered to the distal nephron mostly determines the volume of dilute urine that can be excreted. 
The tubular reabsorption enhancement results in a reduction of the fluids delivered to the distal 
tubule, which itself limits the rate of water excretion [43]. Therefore, we can assume that H4R 
activation, preserving the proximal tubule reabsortive machinery caused a reduction in urine 
volume, without any anti-hyperglycaemic effect.  The balance between H4R and H3R activity in the 
kidney could explain the partial efficacy of H4R antagonism in restoring the basal urine volume. 
Interestingly, we demonstrated that renal H3R is predominantly localized on the collecting duct 
epithelium [7], a major regulator of water reabsorption. Moreover, its expression was up-regulated 
in the kidney of both diabetic rats [7] and DBA2/J mice (Supplementary Fig. 2b), and in a pilot 
study H3R expression in mice positively correlated with urine volume [22]. Therefore, it is possible 
to speculate subsequent to blockade of the H4R, the free histamine binds to the H3R in the collecting 
duct, thus explaining the partial efficacy of H4R antagonism in restoring the basal urine volume.  
A persistent inflammatory environment due to robust inflammatory cells recruitment is recognised 
as one of the major causes of collagen deposition and fibrosis development. Indeed, GFR decline is 
associated with the presence in urine and serum of specific inflammatory markers, such as 
interleukin (IL)-6, monocyte chemoattractant protein (MCP)1, and interferon gamma-induced 
protein (IP)-10 [44]. Interestingly, both glomeruli and tubules play active roles in process. Within 
the glomerulus, podocytes can be considered immune-like cells as they constitutively express Toll-
like receptor 4, which can induce the costimulatory molecule B7.1 expression [45]. Furthermore, 
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podocytes can stimulate specific CD4+ and CD8+ T cell responses, mimicking some of the 
functions of dendritic cells or macrophages of hematopoietic origin [46], thus promoting an 
inflammatory and fibrotic state. On the other side, tubulointerstitial injury contributes to the 
development of diabetic nephropathy. In our study, the establishment of tubular interstitial fibrosis 
sustains the functional injury induced by STZ. Inhibiting the induction of pro-inflammatory and 
pro-fibrotic mediators have already been demonstrated to have renoprotective effects [47]. H4R 
blockade has been reported to exert anti-fibrotic effects through the reduction in transforming 
growth factor (TGF)-ß production and pro-inflammatory events in a model of lung fibrosis [48, 49]. 
Besides TGF-ß, ATP is a known pro-fibrotic stimulus that may regulate renal fibroblast 
proliferation and activity, thus influencing fibroblast to myofibroblast transformation [50], and it is 
also involved in the inflammatory process via histamine release [51]. Moreover, the inhibition of 
chemotaxis by H4R antagonism is well documented for several immune cell types. Accordingly, we 
found a reduced cellular infiltration in the tubular interstitium following JNJ39758979 
administration, whose higher doses were effective in reducing the excess of extracellular matrix 
collagen deposition.  
In conclusion, our data suggest that the H4R participates in diabetic nephropathy through both a 
direct effect on tubular reabsorption, which could lead to an effect on glomerular integrity, and an 
indirect action on renal tissue architecture through inflammatory cell recruitment. Therefore H4R 
antagonism emerges as a possible therapeutic approach to counteract diabetic nephropathy 
development. 
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Supplementary Materials 
 
Creatinine evaluations 
Twenty-five μl of plasma or 5 μl of urine were exposed to cold acidified acetonitrile (1:200 v/v 
glacial acetic acid: acetonitrile) in a ratio of 1:4. After precipitation and dehydration of the sample, 
creatinine was re-suspended in 25 μl of HPLC mobile phase (2.00 l of 5 mM sodium acetate and 
adjusted to pH 4.2 ± 0.1 with 1.4 ml glacial acetic acid; following filtration, 80 ml of methanol and 
20 ml of acetonitrile were added). All reagents were HPLC grade or better. HPLC was performed 
by a  L2 Binary Pump, instrument with a UV-vis spectrophotometer detector (LC 95 PerkinElmer; 
Akron, OH, USA). A polar bonded-phase column Zorbax 300-SCX column (2.1 x 50 mm, 5 μm; 
Agilent Technology, Santa Clara, CA, USA). The flow was set at 0.3 ml min-1, runtime was 10 
minutes. Detection of eluting creatinine peak was achieved at 225 nm at 3.65 ± 0.02 minutes. The 
concentration of creatinine was determined from an external standard regression line (8 points, from 
0.003 to 1.000 mg/dl). The analysis was performed in duplicate. 
 
Morphological analysis quantification 
PAS positive area, indicating matrix mesangial expansion, were analysed using the ImageJ 1.33 
image analysis program (http://rsb.info.nih.gov/ij) upon selection of an appropriate threshold. 
Values are reported as PAS positive glomerulus area compared to the total glomerular area; 
measurements of at least 40 glomeruli for each animal from the different experimental groups were 
performed. 
Optical density measurements of the deep red–stained collagen fibres were carried out by using the 
ImageJ 1.33 image analysis program (http://rsb.info.nih.gov/ij) upon selection of an appropriate 
threshold to include the specific stained tissue and guarantee the exclusion of non-collagen areas. 
Values, reported as arbitrary units, are calculated as surface area × optical density × 10−6; the 
measurements of at least 20 images for individual animals were performed. 
 
Megalin immunofluorescence quantification 
The optical density of ROI was evaluated with the ImageJ 1.33 image analysis program 
(http://rsb.info.nih.gov/ij) upon selection of an appropriate threshold to include the positive area. As 
described above, values, reported as megalin expression over control, are calculated as surface area 
× optical density × 10−6; the measurements of at least 50 images for individual animals were 
performed. 
 
RNA isolation 
Total RNA was isolated by chloroform/phenol RNA extraction with TRIzol Reagent according with 
the manufacturer’s instructions. DNA contamination was removed with DNase (Deoxiribonuclease 
I) prior to the reverse transcription (RT) reaction. The concentration and purity of total RNA were 
evaluated prior and after the DNase treatment by spectrophotometry, measuring the absorbance at 
260 and 280 nm wavelength. The absence of RNA degradation was confirmed by agarose gel 
electrophoresis with ethidium bromide staining.  
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Immunoistochemistry for HDC detection 
Conventional immunohistochemical procedures were employed for the HDC enzyme were 
employed. Briefly, immunoperoxidase staining was performed on 5 µm section for formalin-fixed 
tissue using an appropriate antigen retrieval (10 mM sodium citrate, pH 6.0). After incubation in 
1.5% bovine serum albumin in PBS, pH 7.4 for 20 min at RT to minimise non-specific binding, 
renal sections were incubated overnight at 4 °C with rabbit polyclonal anti-HDC (1:50; HPA038891 
Sigma Aldrich). The immunoreactions were revealed by incubation with the secondary biotinylated 
anti-rabbit (Vector Laboratories, Inc.; Burlingame, CA, USA) antibodyfollowed by a three-layer 
streptavidin–biotin–peroxidase complex staining method (Vectastain ABC Elite kit and 3',3-
diaminobenzadine tetrahydrochloride, DAB; Vector Laboratories, Inc.). Negative controls were 
carried out by omitting the primary antiserum. Stomach corpus from mice was used as positive 
control. All sections were stained or immunostained in a single session to minimize artifactual 
differences in the staining. Stained sections were examined, and pictures were taken with an Zeiss 
Axioskop microscope (Zeiss, Mannheim, DE) at 10X or 25X magnification, respectively. 
 
Immunofluorescence for H 3R and H 4R detection 
After antigen retrieval and blocking, 5 μm kidney paraffin sections were incubated overnight with 
goat polyclonal anti-H4R (sc-33967, lot number L0913; Santa Cruz Biotechnology) or with rabbit 
polyclonal anti-H3R (349–358, produced and validated in the School of Biological and Biomedical 
Sciences, Durham University; 1 μg/ml), followed by incubation with the Alexa Fluor 594 
AffiniPure bovine anti-goat or the Alexa Fluor 594 AffiniPure donkey anti-rabbit (1:350) for 2 h. 
After counterstaining with DAPI, photomicrographs were obtained by a confocal laser-scanning 
microscope The immunoreaction products were observed under an epifluorescence Zeiss Axioskop 
microscope at 40X magnification. 
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